Results 51 to 60 of about 82,478 (265)

Table_3_Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients.docx

, 2023
Immune checkpoint inhibitors (ICIs) including anti-PD-1 and anti-PD-L1 antibodies, have significantly changed the treatment outcomes of NSCLC patients with better overall survival.
Aladdin Kanbour (14442123), Omar Muhammad Khan (14442147), Reyad Mohsin (14442120), Abdul Rehman Zar Gul (14442126), Issam Al-Bozom (4711098), Suma Vijayakumar (14442132), Shaza Abu Sirriya (14442144), Anite Philip (14442129), Mohamed Izham Mohamed Ibrahim (10221287), Shahnaz Qadri (2610634), Ussama Al Homsi (14442150), Said Dermime (79420), Aijaz Parray (290256), Maysaloun Merhi (4246147), Shahab Uddin (154400), Rajaa Al-Abdulla (14442138), Shayista Akbar (14442117), Shereena Hydrose (14442135), Afsheen Raza (492657), Varghese Philipose Inchakalody (14153292), Wafa Abualainin (14442141)   +20 more
core   +1 more source

pH Low Insertion Peptide-Modified Programmed Cell Death-Ligand 1 Potently Suppresses T-Cell Activation Under Acidic Condition

Frontiers in Immunology, 2021
Programmed cell death-ligand 1 (PD-L1)/PD-1 axis is critical for maintenance of immune homeostasis by limiting overactivation of effector T-cell responses.
Ying Sun, Ying Sun, Linhan Hu, Linhan Hu, Peng Yang, Min Zhang, Xinwei Wang, He Xiao, Chunxia Qiao, Jing Wang, Longlong Luo, Jiannan Feng, Yuanqiang Zheng, Yi Wang, Yanchun Shi, Guojiang Chen   +15 more
doaj   +1 more source

Elevated Plasma Soluble PD-L1 Levels in Out-of-Hospital Cardiac Arrest Patients [PDF]

Journal of Clinical Medicine, 2021
Background: A deregulated immune system has been implicated in the pathogenesis of post-cardiac arrest syndrome (PCAS). A soluble form of programmed cell death-1 (PD-1) ligand (sPD-L1) has been found at increased levels in cancer and sustained inflammation, thereby deregulating immune functions.
Miho Sumiyoshi, Eiji Kawamoto, Yuki Nakamori, Ryo Esumi, Kaoru Ikejiri, Toru Shinkai, Yuichi Akama, Asami Ito-Masui, Hiroshi Imai, Arong Gaowa, Eun Jeong Park, Motomu Shimaoka   +11 more
openaire   +2 more sources

Small molecule inhibitors of PD 1 PD L1 immune checkpoint alleviate the PD L1 induced exhaustion of T cells [PDF]

, 2017
Antibodies targeting the PD-1/PD-L1 immune checkpoint achieved spectacular success in anticancer therapy in the recent years. In contrast, no small molecules with cellular activity have been reported so far.
Sylwia Krzanik, Tomala, M., Kocik, J., Lukasz Skalniak, Żak, Krzysztof, Skalniak, Lukasz, Marcin Tomala, Skalniak, L., Pachota, Magdalena, Skalniak, Łukasz, Pyrc, K., Zak, Krzysztof M., Grudnik, Przemyslaw, Bozena Szelazek, Przemyslaw Grudnik, Grudnik, Przemysław, Katarzyna Magiera, Dömling, A., Magiera, Katarzyna, Magiera-Mularz, Katarzyna, Dömling, Alexander, Krzanik, S., Alexander Dömling, Musielak, B., Musielak, Bogdan, Grudnik, P., Zak, Krzysztof M, Magdalena Pachota, Grzegorz Dubin, Bogdan Musielak, Krzysztof Pyrc, Guzik, Katarzyna, Guzik, K., Tad A. Holak, Holak, Tadeusz, Krzysztof M. Zak, Zak, K., Tomala, Marcin, Dubin, Grzegorz, Holak, Tad A, Justyna Kocik, Holak, T., Szelazek, B., Katarzyna Guzik, Kocik, Justyna, Pyrc, Krzysztof, Pachota, M., Dubin, G., Holak, Tad A., Krzanik, Sylwia, Magiera, K., Szelazek, Bozena   +51 more
core   +1 more source

Table_2_Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients.docx

, 2023
Immune checkpoint inhibitors (ICIs) including anti-PD-1 and anti-PD-L1 antibodies, have significantly changed the treatment outcomes of NSCLC patients with better overall survival.
Aladdin Kanbour (14442123), Omar Muhammad Khan (14442147), Reyad Mohsin (14442120), Abdul Rehman Zar Gul (14442126), Issam Al-Bozom (4711098), Suma Vijayakumar (14442132), Shaza Abu Sirriya (14442144), Anite Philip (14442129), Mohamed Izham Mohamed Ibrahim (10221287), Shahnaz Qadri (2610634), Ussama Al Homsi (14442150), Said Dermime (79420), Aijaz Parray (290256), Maysaloun Merhi (4246147), Shahab Uddin (154400), Rajaa Al-Abdulla (14442138), Shayista Akbar (14442117), Shereena Hydrose (14442135), Afsheen Raza (492657), Varghese Philipose Inchakalody (14153292), Wafa Abualainin (14442141)   +20 more
core   +1 more source

Elevated Soluble PD-L1 in Pregnant Women's Serum Suppresses the Immune Reaction [PDF]

Frontiers in Immunology, 2019
Background: Programmed death-ligand 1 (PD-L1) is expressed not only on some cancer cells, but also on the outer surface of placental syncytiotrophoblasts, which is assumed to induce maternal immune tolerance to fetal tissue via programmed death-1 (PD-1) receptors on T cells. Recently, levels of soluble forms of PD-L1 (sPD-L1) were reported to be higher
Mai Okuyama, Mai Okuyama, Hidetoshi Mezawa, Toshinao Kawai, Mitsuyoshi Urashima, Mitsuyoshi Urashima   +5 more
openaire   +3 more sources

Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood

, 2022
Immune checkpoint blockade therapy is a treatment option of various metastatic cancer diseases including renal cell carcinoma (RCC). Approved antibody drugs target the co-inhibitory signaling of Programmed Cell Death Ligand-1 (PD-L1) and its receptor ...
Lingelbach, Susanne, Derigs, Marcus, Wegner, Moritz, Schultz, Carolin, Denkert, Carsten, Keber, Corinna U., Wischmann, Viktoria, Hänze, Jörg, Hofmann, Rainer, Hegele, Axel   +9 more
core   +1 more source

Prognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancer

Cancer Immunology and Immunotherapy, 2023
Programmed cell death-ligand 1 (PD-L1) on tumor cells can be degraded to soluble form (sPD-L1) and enter circulation, however, the clinical significances of sPD-L1 in peripheral blood remains to be elucidated in non-small-cell lung cancer (NSCLC).
K. Teramoto, Tomoyuki Igarashi, Yoko Kataoka, M. Ishida, J. Hanaoka, H. Sumimoto, Y. Daigo   +6 more
semanticscholar   +1 more source

Circular RNA hsa_circ_0000190 Facilitates the Tumorigenesis and Immune Evasion by Upregulating the Expression of Soluble PD-L1 in Non-Small-Cell Lung Cancer

International Journal of Molecular Sciences, 2021
Lung cancer is the leading cause of death from cancer in Taiwan and throughout the world. Immunotherapy has revealed promising and significant efficacy in NSCLC, through immune checkpoint inhibition by blocking programmed cell death protein (PD)-1/PD-1 ...
Yung-Hung Luo, Yi-ping Yang, Chian-Shiu Chien, A. Yarmishyn, Afeez Adekunle Ishola, Yueh Chien, Yuh-Min Chen, P. Tsai, Tzu-Wei Lin, Mong-Lien Wang, S. Chiou   +10 more
semanticscholar   +1 more source

Table_1_Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients.docx

, 2023
Immune checkpoint inhibitors (ICIs) including anti-PD-1 and anti-PD-L1 antibodies, have significantly changed the treatment outcomes of NSCLC patients with better overall survival.
Aladdin Kanbour (14442123), Omar Muhammad Khan (14442147), Reyad Mohsin (14442120), Abdul Rehman Zar Gul (14442126), Issam Al-Bozom (4711098), Suma Vijayakumar (14442132), Shaza Abu Sirriya (14442144), Anite Philip (14442129), Mohamed Izham Mohamed Ibrahim (10221287), Shahnaz Qadri (2610634), Ussama Al Homsi (14442150), Said Dermime (79420), Aijaz Parray (290256), Maysaloun Merhi (4246147), Shahab Uddin (154400), Rajaa Al-Abdulla (14442138), Shayista Akbar (14442117), Shereena Hydrose (14442135), Afsheen Raza (492657), Varghese Philipose Inchakalody (14153292), Wafa Abualainin (14442141)   +20 more
core   +1 more source